This risk-reduction policy supports a straightforward user experience, whether youre testing it for the first time or seeking steady, long-term use
Home Medical news & Guidelines Anesthesiology Cardiology and CTVS Critical Care Dentistry Dermatology Diabetes and Endocrinology ENT Gastroenterology Medicine Nephrology Neurology Obstretics-Gynaecology Oncology Ophthalmology Orthopaedics Pediatrics-Neonatology Psychiatry Pulmonology Radiology Surgery Urology Laboratory Medicine Diet Nursing Paramedical Physiotherapy Health news Fact Check Bone Health Fact Check Brain Health Fact Check Cancer Related Fact Check Child Care Fact Check Dental and oral health fact check Diabetes and metabolic health fact check Diet and Nutrition Fact Check Eye and ENT Care Fact Check Fitness fact check Gut health fact check Heart health fact check Kidney health fact check Medical education fact check Men's health fact check Respiratory fact check Skin and hair care fact check Vaccine and Immunization fact check Women's health fact check AYUSH State News Andaman and Nicobar Islands Andhra Pradesh Arunachal Pradesh Assam Bihar Chandigarh Chattisgarh Dadra and Nagar Haveli Daman and Diu Delhi Goa Gujarat Haryana Himachal Pradesh Jammu & Kashmir Jharkhand Karnataka Kerala Ladakh Lakshadweep Madhya Pradesh Maharashtra Manipur Meghalaya Mizoram Nagaland Odisha Puducherry Punjab Rajasthan Sikkim Tamil Nadu Telangana Tripura Uttar Pradesh Uttrakhand West Bengal Medical Education Industry Retatrutide Shows Remarkable Weight Loss in Phase 3 TRIUMPH-1 Trial In the phase 3 TRIUMPH-1 trial, 2339 adults with obesity or overweight and at least one weight-related comorbidity were randomized to receive retatrutide (4 mg, 9 mg, or 12 mg) or placebo over 80 weeks
Some chemotherapy drugs may cause a metallic taste in the mouth
Our private label GLP-1 Booster formula is strategically developed to allow partners to enter this high-growth category quickly, professionally, and with a clinically positioned product that resonates with modern weight-management consumers
Interesting dynamics will be observed in each country, such as in India, where off-patent semaglutide will enter the market within a year of the launches of both Lillys Mounjaro (launched March 2025) and Novos Wegovy (launched June 2025), marking a short timeframe in which these originators can gain patient share before increased competition
